Shire/Baxalta Merger's Benefits Doubted By Wall Street
This article was originally published in The Pink Sheet Daily
Executive Summary
Although Shire struggled toward this merger for five months and says it will position Shire as the top rare disease company in the world, analysts question the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.
You may also be interested in...
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.
Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.